1Marbury TC, Strange P. Multicenter, randomized comparison of the therapeutic effects of long-term use of repaglinide with glyburide in type 2 diabetes. Diabetes, 1998, 47:A75.
4Hatorp V, Huang WC, Strange P. Pharmacokinetic profiles of Repaglinide in elderly subjects with type 2 diabetes. J Clin Endocrin Metab, 1999, 84:1475-1478.
二级参考文献10
1Hatorp V,Huang WC,Strange P.Pharmacokinetic profiles of repaglinide in elderly subjects with type 2 diabetes[].The Journal of Clinical Endocrinology.1999
2Vinambres C,Villanueva-penacarrillo ML,Malaisse WJ.Repaglinide preserves nutrient-stimulated biosynthetic activity in rat pancreatic islets[].Pharmacological Research.1996
3Marbury TC,Hatorp V,Damsbo P,et al.Repaglinide can be given in the flexible preprandial dosing regimen in patients with type 2 diabetes[].Diabetes.1998
4Goldberg RB,Brodows RG,Damsbo P.A randomized, placebocontrolled trial of repaglinide in the treatment of type 2 diabetes[].Diabetes.1998
5Berger S,Strange P.Repaglinide, a novel oral hypoglycemic agent in type 2 diabetes: A randomized, placebo-controlled, double-blind, fixed-dose study[].Diabetes.1998
6Fuhlendorff J,Rorsman P,Kofod H,et al.Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes[].Diabetes.1998
7Owens DR,Luzio SD,Coates PA.Insulin secretion and sensitivity in newly diagnosed NIDDM Caucasions in the UK[].Diabetic Medicine.1996
8Marbury TC,Strange P.Multicenter, randomized comparison of the therapeutic effects of long-term use of repaglinide with glyburide in type 2 diabetes[].Diabetes.1998
9Damsbo P,Clauson P,Marbury TC,et al.A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetes patients[].Diabetes Care.1999
10Marbury TC,Hatorp V.Pharmacokinetics of repaglinide after single and multiple doses in patients with renal impairment compared with normal healthy volunteers[].Diabetes.1998
